<i>In Vitro</i> and <i>In Vivo</i> Activity of Gepotidacin against Drug-Resistant Mycobacterial Infections-Reference-Cited by-同舟云学术

In Vitro and In Vivo Activity of Gepotidacin against Drug-Resistant Mycobacterial Infections

Published:2022-12-20 Issue:12 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ahmad Mohammad Naiyaz¹²^ORCID,Garg Tanu¹²^ORCID,Singh Shriya¹^ORCID,Shukla Richa¹,Malik Pradip¹²,Krishnamurthy Ramya V.³,Kaur Parvinder³^ORCID,Chopra Sidharth¹²^ORCID,Dasgupta Arunava¹²^ORCID

Affiliation:

1. Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India

2. Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India

3. Foundation for Neglected Diseases Research (FNDR), Bangalore, Karnataka, India

Abstract

Mycobacterial pathogens, including nontuberculous mycobacteria (NTM) and Mycobacterium tuberculosis , are pathogens of significant worldwide interest owing to their inherent drug resistance to a wide variety of FDA-approved drugs as well as causing a broad range of serious infections. Identifying new antibiotics active against mycobacterial pathogens is an urgent unmet need, especially those antibiotics that can bypass existing resistance mechanisms.

Funder

Department of Biotechnology, Ministry of Science and Technology, India

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00564-22

Reference34 articles.

1. Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria

2. Interaction between DNA Gyrase and Quinolones: Effects of Alanine Mutations at GyrA Subunit Residues Ser 83 and Asp 87

3. Fluoroquinolones in the Treatment of Tuberculosis: Which Is Best?

4. The role of moxifloxacin in tuberculosis therapy

5. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India;Agrawal D;Int J Tuber Lung Dis,2009

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antistaphylococcal discovery pipeline; where are we now?;European Journal of Medicinal Chemistry;2024-02

2. Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans;ACS Infectious Diseases;2024-01-31

3. Alternative therapies against Mycobacterium abscessus infections;Clinical Microbiology and Infection;2023-11

4. Treatment of non-tuberculosis mycobacteria skin infections;Frontiers in Pharmacology;2023-09-05

5. Antibiotics in the clinical pipeline as of December 2022;The Journal of Antibiotics;2023-06-08